S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Forget NVDA. Buy this A.I. stock instead (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Forget NVDA. Buy this A.I. stock instead (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Forget NVDA. Buy this A.I. stock instead (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Forget NVDA. Buy this A.I. stock instead (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:ALLO

Allogene Therapeutics (ALLO) Stock Forecast, Price & News

$3.65
-0.07 (-1.88%)
(As of 09/22/2023 ET)
Compare
Today's Range
$3.63
$3.81
50-Day Range
$3.65
$5.41
52-Week Range
$3.63
$12.21
Volume
1.51 million shs
Average Volume
1.60 million shs
Market Capitalization
$611.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.35

Allogene Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.64 Rating Score
Upside/​Downside
347.8% Upside
$16.35 Price Target
Short Interest
Bearish
30.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.58mentions of Allogene Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$42,900 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.25) to ($2.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

471st out of 965 stocks

Biological Products, Except Diagnostic Industry

73rd out of 160 stocks


ALLO stock logo

About Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

ALLO Price History

ALLO Stock News Headlines

5 Best High Risk High Reward Stocks To Buy Now
Biden's latest bailout--terrible for America?
And a consultant for the Dept. of Defense (Joel Litman) says this is all leading to an event in the next 20 months that could help some get vastly wealthier… but also make it harder than ever to hang onto any money you make.This might be the most important development affecting you and your money over the next few years—
16 Most Shorted Stocks Right Now
William Blair Sticks to Its Buy Rating for Arcellx Inc (ACLX)
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
Allogene Therapeutics (ALLO) Gets a Buy from RBC Capital
Analyst Ratings for Allogene Therapeutics
Allogene Therapeutics (NASDAQ: ALLO)
See More Headlines
Receive ALLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALLO Company Calendar

Last Earnings
8/02/2023
Today
9/24/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALLO
Fax
N/A
Employees
359
Year Founded
2018

Price Target and Rating

Average Stock Price Forecast
$16.35
High Stock Price Forecast
$31.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+347.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
11 Analysts

Profitability

Net Income
$-332,630,000.00
Net Margins
-184,733.34%
Pretax Margin
-184,733.33%

Debt

Sales & Book Value

Annual Sales
$240,000.00
Book Value
$4.62 per share

Miscellaneous

Free Float
121,696,000
Market Cap
$611.85 million
Optionable
Not Optionable
Beta
0.77

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Arie S. Belldegrun F.A.C.S. (Age 74)
    FACS, M.D., Co-Founder & Exec. Chairman
    Comp: $714.25k
  • Dr. David D. Chang M.D. (Age 63)
    Ph.D., Co-Founder, Pres, CEO & Director
    Comp: $1.1M
  • Mr. Joshua A. Kazam (Age 46)
    Co-Founder & Director
    Comp: $711k
  • Yinlin Chen
    Sr. VP of Fin.
  • Mr. Timothy L. Moore Ph.D. (Age 62)
    Exec. VP & Chief Technical Officer
  • Ms. Barbra Sasu
    Chief Scientific Officer
  • Mr. Stephen Cheng
    Chief Information Officer
  • Mr. Earl M. Douglas Esq. (Age 60)
    Gen. Counsel & Compliance Officer
  • Ms. Susan R. Lundeen (Age 57)
    Chief People Officer
  • Ms. Christine Cassiano
    Exec. VP, Chief Corp. Affairs & Brand Strategy Officer













ALLO Stock - Frequently Asked Questions

Should I buy or sell Allogene Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALLO shares.
View ALLO analyst ratings
or view top-rated stocks.

What is Allogene Therapeutics' stock price forecast for 2023?

11 analysts have issued twelve-month price targets for Allogene Therapeutics' shares. Their ALLO share price forecasts range from $6.00 to $31.00. On average, they anticipate the company's share price to reach $16.35 in the next twelve months. This suggests a possible upside of 347.8% from the stock's current price.
View analysts price targets for ALLO
or view top-rated stocks among Wall Street analysts.

How have ALLO shares performed in 2023?

Allogene Therapeutics' stock was trading at $6.29 at the start of the year. Since then, ALLO shares have decreased by 42.0% and is now trading at $3.65.
View the best growth stocks for 2023 here
.

When is Allogene Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our ALLO earnings forecast
.

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) issued its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.06. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.01 million. Allogene Therapeutics had a negative net margin of 184,733.34% and a negative trailing twelve-month return on equity of 54.13%. The business's revenue was down 48.8% on a year-over-year basis. During the same period last year, the company posted ($0.52) EPS.

What is David Chang's approval rating as Allogene Therapeutics' CEO?

2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

When did Allogene Therapeutics IPO?

(ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

What is Allogene Therapeutics' stock symbol?

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (5.06%), BlackRock Inc. (5.04%), JPMorgan Chase & Co. (3.66%), Woodline Partners LP (3.17%), Geode Capital Management LLC (1.09%) and Goldman Sachs Group Inc. (0.89%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Owen N Witte, Owen N Witte, Rafael Amado, Stephen Mayo and Veer Bhavnagri.
View institutional ownership trends
.

How do I buy shares of Allogene Therapeutics?

Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allogene Therapeutics' stock price today?

One share of ALLO stock can currently be purchased for approximately $3.65.

How much money does Allogene Therapeutics make?

Allogene Therapeutics (NASDAQ:ALLO) has a market capitalization of $611.85 million and generates $240,000.00 in revenue each year. The company earns $-332,630,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis.

How many employees does Allogene Therapeutics have?

The company employs 359 workers across the globe.

How can I contact Allogene Therapeutics?

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.allogene.com. The company can be reached via phone at (650) 457-2700 or via email at ir@allogene.com.

This page (NASDAQ:ALLO) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -